Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE BrokerBank Securities, Inc.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is marketed and distributed in the U.S. by EXEL, and in Europe by Sobi. Sobi receives an undisclosed management fee. European revenues are expected in Q2 after a March European approval. Cabo is currently only approved to treat a specific type of thyroid cancer, MTC. There are between 500-700 new cases per year in the U.S., and treatment costs $10,395 for a 28-day supply. In addition, the company has five phase-three trials for various cancer treatments. On top of those, the company has numerous partnerships with other drug companies, and multiple treatments in phase two trials. EXEL has a huge pipeline of potential uses for cabo and cobi.
The company's stock has been hammered by short sellers and recent events. The stock price is down 64% from its 52-week high of $8.41 and now trades at $3.64. The short interest as a percentage of the float is 27%. People are very bearish on EXEL. The price tanked after news in March from the mid-point of one of the company's phase-three trials. I believe the potential is there run the stock price to run back up.
A full in-depth analyst report on CBDS that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Fred Rockwell, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
©2012 PR Newswire. All Rights Reserved.